Sign in
WithdrawnPhase 1

A Safety Study of Brentuximab Vedotin in Participants With HIV

Key facts

Who runs it
Seagen Inc.
Where
Chicago and San Francisco, United StatesSee the 2 sites
Trial code
Status
Withdrawn
Phase
Phase 1
Started
31 Dec 2022
Ended
31 May 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • brentuximab vedotin
  • Placebo
  • ART
Record updated
14 February 2023
Why it stopped
Study withdrawn due to low patient accrual.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • HIV-1 seropositive with documentation of infection
  • Immunological nonresponder, defined as:; Has been on ART with an HIV viral load <50 copies/mL for at least 24 months; Has a CD4+ T-cell lymphocyte count between 51 to 200 cells/µL
  • Life expectancy of >9 months
  • Participant is negative for hepatitis B, or if infected with hepatitis B, receiving anti-hepatitis B therapy
  • Participants with a history of hepatitis C virus (HCV) are eligible if they have completed therapy for HCV and show sustained virologic remission (12 weeks or more)

Who cannot take part

  • Prior clinical John Cunningham virus (JCV) infection, history of JCV identified in cerebrospinal fluid, or presence of JCV antibodies at screening
  • Any immunomodulating therapy (excluding premedication steroid) within 4 weeks prior to the screening visit
  • Any currently active AIDS-defining illness per Category C conditions according to the CDC Classification System for HIV Infection, with the following exceptions:; Limited cutaneous Kaposi's sarcoma not currently requiring systemic therapy; Wasting syndrome due to HIV or any other AIDS-defining illness for which no therapeutic treatment is required OR the required treatment is not included in the list of prohibited medications
  • Acute liver disease or any other active infection secondary to HIV requiring acute therapy
  • History of progressive multifocal leukoencephalopathy (PML)
  • Prior malignancy within 2 years other than cutaneous basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, anal intraepithelial neoplasia, or cutaneous Kaposi's sarcoma
  • Cirrhosis secondary to any cause

Where in United States

  • University of Illinois at ChicagoChicago, United States
  • University of California at San FranciscoSan Francisco, United States

About the trial

What the trial wants to find out

This study will test brentuximab vedotin to see if it is safe for people with human immunodeficiency virus (HIV) who have low CD4+ and have received antiretroviral therapy (ART) treatment. It will also see if brentuximab vedotin raises CD4+ counts. It will study the side effects of this drug as well. A side effect is anything a drug does to the body besides treating the disease.

Read full original descriptionShow less

In this study participants will be assigned randomly to a group. Participants will get either brentuximab vedotin or placebo. A placebo looks like the drug but does not contain any medicine in it. All participants will keep getting ART during the study.

The 2 groups in the trial

  • Brentuximab vedotin + ARTTreatment being tested

    Brentuximab vedotin given on Day 1 and Day 15. ART will be given throughout the study.

    Treatment: brentuximab vedotin and ART

  • Placebo + ARTPlacebo, for comparison

    Placebo given on Day 1 and Day 15. ART will be given throughout the study.

    Treatment: Placebo and ART

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1, Single-blind, Dose-escalation Study to Assess the Safety and Tolerability of Brentuximab Vedotin (ADCETRIS®) in Subjects With Human Immunodeficiency Virus (HIV)
Record updated
14 February 2023